Skip to main content
. 2020 Jul-Dec;10(2):68–75. doi: 10.5005/jp-journals-10018-1327

Table 4.

Treatment approaches of patients with COVID-19

Variables Total (n = 199) Discharged (n = 122) Expired (n = 77) p-value
Treatments approaches
  Tocilizumab single dose - no. (%) 102 73 (72) 29 (28) <0.01
  Tocilizumab double doses - no. (%) 48 10 (21) 38 (79) <0.001
  Tocilizumab triple doses - no. (%) 3 2 (66) 1 (33) 0.849
  Bevacizumab - no. (%) 25 23 (92) 2 (8) <0.001
  Tocilizumab plus Bevacizumab - no. (%) 21 14 (66) 7 (34) 0.596